Genetics, genomics, and cancer risk assessment

Ca-A Cancer Journal for Clinicians

61, 327-359

DOI: 10.3322/caac.20128

Citation Report

#	Article	IF	Citations
1	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
2	The Front Line of Genomic Translation. Journal of Cancer Epidemiology, 2012, 2012, 1-3.	0.5	0
3	Genetic Risk Assessments in Individuals at High Risk for Inherited Breast Cancer in the Breast Oncology Care Setting. Cancer Control, 2012, 19, 255-266.	0.7	37
4	Epigenetics and the Transition from Acute to Chronic Pain. Pain Medicine, 2012, 13, 1474-1490.	0.9	116
5	Closing the loop: an interactive action-research conference format for delivering updated medical information while eliciting Latina patient/family experiences and psychosocial needs post-genetic cancer risk assessment. Familial Cancer, 2012, 11, 449-458.	0.9	9
6	Risk Prediction Models for Colorectal Cancer: A Review. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 398-410.	1.1	84
7	A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. BMC Medical Genomics, 2012, 5, 28.	0.7	71
8	Translating cancer â€˜omicsâ€™ to improved outcomes: Figure 1.. Genome Research, 2012, 22, 188-195.	2.4	107
9	Impact of Web-Based Case Conferencing on Cancer Genetics Training Outcomes for Community-Based Clinicians. Journal of Cancer Education, 2012, 27, 217-225.	0.6	21
10	Predictive models for mutations in mismatch repair genes: implication for genetic counseling in developing countries. BMC Cancer, 2012, 12, 64.	1.1	11
11	Hereditary cancer syndromes: opportunities and challenges. BMC Proceedings, 2013, 7, K14.	1.8	3
12	Integration of Genomics in Cancer Care. Journal of Nursing Scholarship, 2013, 45, 43-51.	1.1	20
13	Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool. Patient Education and Counseling, 2013, 92, 188-196.	1.0	23
14	Nursing Genomics. Nursing Clinics of North America, 2013, 48, 523-556.	0.7	3
15	An Overview of Epigenetics in Nursing. Nursing Clinics of North America, 2013, 48, 649-659.	0.7	15
16	Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results. Patient Education and Counseling, 2013, 93, 413-419.	1.0	26
17	Practice Considerations in Providing Cancer Risk Assessment and Genetic Testing in Women's Health. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2013, 42, 274-286.	0.2	3
18	Hereditary cancer risk assessment: essential tools for a better approach. Hereditary Cancer in Clinical Practice, 2013, 11, 16.	0.6	8

#	Article	IF	Citations
19	A focus group study on breast cancer risk presentation: one format does not fit all. European Journal of Human Genetics, 2013, 21, 719-724.	1.4	17
20	Citizens' perspectives on personalized medicine: a qualitative public deliberation study. European Journal of Human Genetics, 2013, 21, 1197-1201.	1.4	38
21	Allocation of Work Activities in a Comprehensive Cancer Genetics Program. Clinical Journal of Oncology Nursing, 2013, 17, 397-404.	0.3	8
22	Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States. ISRN Oncology, 2013, 2013, 1-8.	2.1	8
23	Genetic Epidemiology of Breast Cancer. , 2013, , 1113-1125.		0
24	Age at Diagnosis May Trump Family History in Driving BRCA Testing in a Population of Breast Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1778-1785.	1.1	5
25	Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. Journal of Clinical Oncology, 2013, 31, 210-216.	0.8	140
26	Variants of uncertain significance in <scp>BRCA</scp> testing: evaluation of surgical decisions, risk perception, and cancer distress. Clinical Genetics, 2013, 84, 464-472.	1.0	88
27	Personalized medicine and access to health care: potential for inequitable access?. European Journal of Human Genetics, 2013, 21, 143-147.	1.4	45
29	Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1in a patient with bilateral breast and endometrial adenocarcinoma. BMC Medical Genetics, 2013, 14, 129.	2.1	17
30	Translating Genomics in Cancer Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1343-1353.	2.3	63
31	Ordering the Correct Genetic Test: Implications for Oncology and Primary Care Healthcare Professionals. Clinical Journal of Oncology Nursing, 2013, 17, 128-131.	0.3	4
32	The role of the monoamine oxidase A gene in moderating the response to adversity and associated antisocial behavior: a review. Psychology Research and Behavior Management, 2014, 7, 185.	1.3	13
33	Pharmacopuncture for Cancer Care: A Systematic Review. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-14.	0.5	25
34	Providing Care for Previvors: Implications for Oncology Nurses. Clinical Journal of Oncology Nursing, 2014, 18, 21-24.	0.3	8
35	Personalized Medicine, Genomics, and Pharmacogenomics. Clinical Journal of Oncology Nursing, 2014, 18, 437-441.	0.3	13
36	Are we ready for personalized cancer risk management? The view from breastâ€care providers. International Journal of Nursing Practice, 2014, 20, 39-45.	0.8	12
37	An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe. Public Health Genomics, 2014, 17, 287-298.	0.6	86

#	Article	IF	Citations
38	RE: Cowden Syndrome and PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria. Journal of the National Cancer Institute, 2014, 106, dju130.	3.0	9
39	Improving Referral for Genetic Risk Assessment in Ovarian Cancer Using an Electronic Medical Record System. International Journal of Gynecological Cancer, 2014, 24, 1003-1009.	1.2	24
40	Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital. Journal of Genetic Counseling, 2014, 23, 108-113.	0.9	3
41	Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan. Breast Cancer, 2014, 21, 656-663.	1.3	8
42	Assessing the Integration of Genomic Medicine in Genetic Counseling Training Programs. Journal of Genetic Counseling, 2014, 23, 679-688.	0.9	6
43	Clinical Applications of Melanoma Genetics. Current Treatment Options in Oncology, 2014, 15, 336-350.	1.3	10
44	Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. Clinical Genetics, 2014, 85, 49-53.	1.0	32
45	Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. Breast Cancer Research and Treatment, 2014, 148, 415-421.	1.1	15
46	Cancer Genomics and Inherited Risk. Journal of Clinical Oncology, 2014, 32, 687-698.	0.8	121
47	From Observation to Intervention: Development of a Psychoeducational Intervention to Increase Uptake of BRCA Genetic Counseling Among High-Risk Breast Cancer Survivors. Journal of Cancer Education, 2014, 29, 709-719.	0.6	14
48	Awareness of Cancer Susceptibility Genetic Testing. American Journal of Preventive Medicine, 2014, 46, 440-448.	1.6	107
49	Personalized Medicine: Review and Perspectives of Promising Baseline EEG Biomarkers in Major Depressive Disorder and Attention Deficit Hyperactivity Disorder. Neuropsychobiology, 2015, 72, 229-240.	0.9	127
50	Cancer classification in the genomic era: five contemporary problems. Human Genomics, 2015, 9, 27.	1.4	48
51	Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Frontiers in Oncology, 2015, 5, 208.	1.3	109
52	Costs of genetic testing: Supporting Brazilian Public Policies for the incorporating of molecular diagnostic technologies. Genetics and Molecular Biology, 2015, 38, 332-337.	0.6	14
53	Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender. Tumor Biology, 2015, 36, 7817-7830.	0.8	5
54	Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings. Genetic Testing and Molecular Biomarkers, 2015, 19, 657-665.	0.3	42
55	Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Modern Pathology, 2015, 28, 14-29.	2.9	172

#	Article	IF	Citations
56	Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. Genetics in Medicine, 2015, 17, 43-50.	1.1	36
57	Applying Public Health Screening Criteria: How Does Universal Newborn Screening Compare to Universal Tumor Screening for Lynch Syndrome in Adults with Colorectal Cancer?. Journal of Genetic Counseling, 2015, 24, 409-420.	0.9	8
58	Hypothesis on the Treatment of Gliomas with Acupuncture at the Primo Node Corresponding to Zusanli (ST 36). Medical Acupuncture, 2015, 27, 144-150.	0.3	6
59	The Genetics of Breast Cancer. Surgical Oncology Clinics of North America, 2015, 24, 705-732.	0.6	5
60	Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. Genetics in Medicine, 2015, 17, 726-732.	1.1	17
61	Personalized Medicine Through SNP Testing for Breast Cancer Risk: Clinical Implementation. Journal of Genetic Counseling, 2015, 24, 744-751.	0.9	14
62	Preâ€test genetic counseling services for hereditary breast and ovarian cancer delivered by nonâ€genetics professionals in the state of Florida. Clinical Genetics, 2015, 87, 473-477.	1.0	59
63	Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer, 2015, 121, 372-378.	2.0	78
64	Hereditary Cancer: Example of a Public Health Approach to Ensure Population Health Benefits of Genetic Medicine. Healthcare (Switzerland), 2016, 4, 6.	1.0	10
65	Self-reported cancer family history is a useful tool for identification of individuals at risk of hereditary cancer predisposition syndrome at primary care centers in middle-income settings: a longitudinal study. Genetics and Molecular Biology, 2016, 39, 178-183.	0.6	15
66	Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era. Genetics and Molecular Biology, 2016, 39, 184-188.	0.6	8
67	Introduction to cancer genetic susceptibility syndromes. Hematology American Society of Hematology Education Program, 2016, 2016, 293-301.	0.9	25
68	Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. Journal of Community Genetics, 2016, 7, 177-183.	0.5	39
69	The future of clinical cancer genomics. Seminars in Oncology, 2016, 43, 615-622.	0.8	23
70	The Evolution of Epigenetics: From Prokaryotes to Humans and Its Biological Consequences. Genetics & Epigenetics, 2016, 8, GEG.S31863.	2.5	52
71	Disparities in Cancer Genetic Risk Assessment and Testing. Oncology Nursing Forum, 2016, 43, 519-523.	0.5	27
72	Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer. JAMA Oncology, 2016, 2, 723.	3.4	10
73	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108

#	Article	IF	Citations
74	Use of BRCA Mutation Test in the U.S., 2004â€“2014. American Journal of Preventive Medicine, 2017, 52, 702-709.	1.6	64
75	Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer. Scientific Reports, 2017, 7, 37984.	1.6	35
76	Primary care providersâ€™ cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda. Journal of General Internal Medicine, 2017, 32, 315-324.	1.3	96
78	Translation and adaptation of skin cancer genomic risk education materials for implementation in primary care. Journal of Community Genetics, 2017, 8, 53-63.	0.5	19
79	Genetic Testing and Psychology. , 2017, , 445-457.		0
80	Issues Arising in Psychological Consultations to Help Parents Talk to Minor and Young Adult Children about their Cancer Genetic Test Result: a Guide to Providers. Journal of Genetic Counseling, 2017, 26, 251-260.	0.9	13
81	Genetic Testing: Challenges and Changes in Testing for Hereditary Cancer Syndromes. Clinical Journal of Oncology Nursing, 2017, 21, 589-598.	0.3	4
82	Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer. Scientific Reports, 2017, 7, 10117.	1.6	391
83	Apply Resources to Practice: Use Current Genetics and Genomics Content in Oncology. Clinical Journal of Oncology Nursing, 2017, 21, 34-38.	0.3	4
84	Evaluation of psychosocial aspects in participants of cancer genetic counseling. Hereditary Cancer in Clinical Practice, 2017, 15, 13.	0.6	4
85	Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk. Familial Cancer, 2018, 17, 495-505.	0.9	17
86	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. Journal of Genetic Counseling, 2018, 27, 854-862.	0.9	5
87	Young Women's Perceptions Regarding Communication with Healthcare Providers About Breast Cancer, Risk, and Prevention. Journal of Women's Health, 2018, 27, 162-170.	1.5	13
88	The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Familial Cancer, 2018, 17, 235-245.	0.9	29
89	Somatic TP53 variants frequently confound germ-line testing results. Genetics in Medicine, 2018, 20, 809-816.	1.1	91
90	Outcomes of Chemotherapy for Microsatellite Instableâ€“High Metastatic Colorectal Cancers. JCO Precision Oncology, 2018, 2, 1-10.	1.5	15
91	Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer. Cancers, 2018, 10, 435.	1.7	67
92	Men seeking counselling in a Breast Cancer Risk Evaluation Clinic. Ecancermedicalscience, 2018, 12, 804.	0.6	5

#	Article	IF	Citations
93	Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family. Scientific Reports, 2018, 8, 11635.	1.6	30
94	The role of BRCA1/2 in hereditary and familial breast and ovarian cancers. Molecular Genetics & Genomic Medicine, 2019, 7, e879.	0.6	34
95	Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics. Hastings Center Report, 2019, 49, S44-S52.	0.7	15
96	The new genomic medicine service and implications for patients. Clinical Medicine, 2019, 19, 273-277.	0.8	34
97	Pathogenic Loss-of-Function Germline TERT Mutations in Patients With Solid Tumors. JCO Precision Oncology, 2019, 3, 1-5.	1.5	2
98	Genetics of gastric cancer: what do we know about the genetic risks?. Translational Gastroenterology and Hepatology, 2019, 4, 55-55.	1.5	30
99	Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCAâ€negative Hispanics with breast cancer. Cancer, 2019, 125, 2829-2836.	2.0	43
100	The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients. Journal of the American Geriatrics Society, 2019, 67, 884-888.	1.3	11
101	Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world. PLoS ONE, 2019, 14, e0213746.	1.1	10
102	Impacts of apolipoprotein E disclosure on healthy Asian older adults: a cohort study. International Psychogeriatrics, 2019, 31, 1499-1507.	0.6	3
103	Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population. BMC Cancer, 2019, 19, 118.	1.1	13
104	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. JCO Precision Oncology, 2019, 3, 1-15.	1.5	7
105	Comparison and analysis of lncRNA-mediated ceRNA regulation in different molecular subtypes of glioblastoma. Molecular Omics, 2019, 15, 406-419.	1.4	7
106	How Should Decision Aids Be Used During Counseling to Help Patients Who Are â€œGenetically at Riskâ€?. AMA Journal of Ethics, 2019, 21, E865-872.	0.4	2
107	Genome analysis and knowledge-driven variant interpretation with TGex. BMC Medical Genomics, 2019, 12, 200.	0.7	30
108	Integrative Analysis of CD133 mRNA in Human Cancers Based on Data Mining. Stem Cell Reviews and Reports, 2019, 15, 23-34.	5.6	7
109	Experience Gained from the Development and Execution of a Multidisciplinary Multi-syndrome Hereditary Colon Cancer Family Conference. Journal of Cancer Education, 2019, 34, 1204-1212.	0.6	3
110	BRCA testing in unaffected young women in the United States, 2006â€2017. Cancer, 2020, 126, 337-343.	2.0	15

#	Article	IF	Citations
111	Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma. Ophthalmology, 2020, 127, 668-678.	2.5	27
112	BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan. Scientific Reports, 2020, 10, 17573.	1.6	15
113	Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice. Journal of Personalized Medicine, 2020, 10, 56.	1.1	11
114	Knowledge, Attitudes, Willingness to Pay, and Patient Preferences About Genetic Testing and Subsequent Risk Management for Cancer Prevention. Journal of Cancer Education, 2022, 37, 362-369.	0.6	10
115	Randomized controlled trial on the effectiveness of webâ€based Genomics Nursing Education Intervention for undergraduate nursing students: a study protocol. Journal of Advanced Nursing, 2020, 76, 3136-3146.	1.5	7
116	Genetic Variability in the microRNA Binding Sites of BMPR1B, TGFBR1, IQGAP1, KRAS, SETD8 and RYR3 and Risk of Breast Cancer in Colombian Women . OncoTargets and Therapy, 2020, Volume 13, 12281-12287.	1.0	2
117	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Global Oncology, 2020, 6, 439-452.	0.8	25
118	The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations. Journal of Clinical Medicine, 2020, 9, 2125.	1.0	8
119	The role of genomics in global cancer prevention. Nature Reviews Clinical Oncology, 2021, 18, 116-128.	12.5	22
120	Aptamerâ€“Exosomes for Tumor Theranostics. ACS Sensors, 2021, 6, 1418-1429.	4.0	20
121	Germline mutations and age at onset of lung adenocarcinoma. Cancer, 2021, 127, 2801-2806.	2.0	14
122	Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico. JCO Global Oncology, 2021, 7, 992-1002.	0.8	6
123	Highly multiplexed rapid DNA detection with single-nucleotide specificity via convective PCR in a portable device. Nature Biomedical Engineering, 2021, 5, 702-712.	11.6	41
124	Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. Npj Breast Cancer, 2021, 7, 107.	2.3	13
125	Association of Population Screening for Breast Cancer Risk With Use of Mammography Among Women in Medically Underserved Racial and Ethnic Minority Groups. JAMA Network Open, 2021, 4, e2123751.	2.8	16
126	The Awareness and Perception of Health Care Specialists about Precision Medicine. Journal of Pharmaceutical Research International, 0, , 8-14.	1.0	0
127	BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?. PLoS ONE, 2017, 12, e0187630.	1.1	29
128	Diurnal variation of steroid hormones and their reference intervals using mass spectrometric analysis. Endocrine Connections, 2018, 7, 1354-1361.	0.8	36

#	Article	IF	Citations
129	BRCAGenetic Testing and Receipt of Preventive Interventions Among Women Aged 18â€“64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas â€" United States, 2009â€“2014. MMWR Surveillance Summaries, 2017, 66, 1-11.	18.6	33
130	The Brazilian Hereditary Cancer Network: historical aspects and challenges for clinical cancer genetics in the public health care system in Brazil. Genetics and Molecular Biology, 2016, 39, 163-165.	0.6	12
131	Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genetics and Molecular Biology, 2014, 37, 234-240.	0.6	34
132	Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing. Translational Cancer Research, 2019, 8, 2893-2905.	0.4	5
133	Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing. Current Medicinal Chemistry, 2020, 27, 2322-2334.	1.2	6
134	Development of a Communication Protocol for Telephone Disclosure of Genetic Test Results for Cancer Predisposition. JMIR Research Protocols, 2014, 3, e49.	0.5	26
135	Genetic Cancer Risk Assessment for Breast Cancer in Latin America. Revista De Investigacion Clinica, 2017, 69, 94-102.	0.2	26
140	Knowledge and Awareness on Personalized Medicine amongst Health Care Specialists and University Students in Health Colleges in Saudi Arabia. Journal of Pharmaceutical Research International, 0, , 177-183.	1.0	2
143	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. Genetics in Medicine, 2022, 24, 564-575.	1.1	8
144	Investigating menâ€™s motivations to engage in genetic screening for BRCA1 and BRCA2 mutations. PLoS ONE, 2022, 17, e0265387.	1.1	3
145	BRCA testing and testing results among women 18â€“65Âyears old. Preventive Medicine Reports, 2022, 26, 101738.	0.8	3
147	Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment. Genes, 2022, 13, 682.	1.0	1
148	Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group. Current Oncology Reports, 2022, 24, 843-860.	1.8	6
149	Crossâ€sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment. Journal of Genetic Counseling, 0, , .	0.9	0
150	The Profile of Articles on AXIN2 Mutations, Oligodontia, and Ethical Statements in Dental Research. Journal of Empirical Research on Human Research Ethics, 0, , 155626462211168.	0.6	0
151	Use of family history taking for hereditary neoplastic syndromes screening in primary health care: A systematic review protocol. PLoS ONE, 2022, 17, e0271286.	1.1	8
152	A qualitative reflexive thematic analysis into the experiences of being identified with a BRCA1/2 gene alteration: â€œSo many little, little traumas could have been avoidedâ€• BMC Health Services Research, 2022, 22, .	0.9	2
154	What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer?. Frontiers in Oncology, 0, 12, .	1.3	0

#	Article	IF	Citations
155	Ethical implications of genetic testing of susceptibility to breast cancer. Revista Bioetica, 2022, 30, 636-643.	0.0	0
156	Implicaciones Ã©ticas de las pruebas genÃ©ticas de susceptibilidad al cÃ¡ncer de mama. Revista Bioetica, 2022, 30, 636-643.	0.0	0
157	ImplicaÃ§Ãµes Ã©ticas dos testes genÃ©ticos de suscetibilidade ao cÃ¢ncer de mama. Revista Bioetica, 2022, 30, 636-643.	0.0	0
158	Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer. Frontiers in Genetics, 0, 13, .	1.1	0
159	Physiciansâ€™ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China. Journal of Personalized Medicine, 2022, 12, 2021.	1.1	3
160	Different perspectives on translational genomics in personalized medicine. Journal of the Turkish German Gynecology Association, 2022, 23, 314-321.	0.2	1
161	Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study. BMC Medical Genomics, 2023, 16, .	0.7	3
163	Oncogenetics and Status of Cancer Patients: bioethical and legal foundations. Revista Bioetica, 2022, 30, 705-714.	0.0	0
164	OncogenÃ©tica y Estatuto de la Persona con CÃ¡ncer: fundamentos bioÃ©tico-legales. Revista Bioetica, 2022, 30, 705-714.	0.0	0
165	OncogenÃ©tica e Estatuto da Pessoa com CÃ¢ncer: fundamentos bioÃ©tico-jurÃdicos. Revista Bioetica, 2022, 30, 705-714.	0.0	0
166	â€œThere's gonna Be a lot more heartacheâ€¦ Coping with a BRCA1/2 alteration: A qualitative reflexive thematic analysis. European Journal of Oncology Nursing, 2023, , 102328.	0.9	0